See more : Drone Guarder, Inc. (DRNG) Income Statement Analysis – Financial Results
Complete financial analysis of Changchun BCHT Biotechnology Co. (688276.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Changchun BCHT Biotechnology Co., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Biora Therapeutics, Inc. (BIOR) Income Statement Analysis – Financial Results
- Imaging Dynamics Company Ltd. (IDYLF) Income Statement Analysis – Financial Results
- Molecule Holdings Inc. (MLCL.CN) Income Statement Analysis – Financial Results
- Frasers Group plc (SDIPF) Income Statement Analysis – Financial Results
- Indraprastha Gas Limited (IGL.BO) Income Statement Analysis – Financial Results
Changchun BCHT Biotechnology Co. (688276.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bchtpharm.com
About Changchun BCHT Biotechnology Co.
Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. Its products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. The company was founded in 2004 and is based in Changchun, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.81B | 1.07B | 1.20B | 1.44B | 975.67M | 1.02B | 690.62M |
| Cost of Revenue | 213.34M | 137.22M | 140.75M | 168.43M | 93.89M | 112.63M | 76.27M |
| Gross Profit | 1.60B | 934.22M | 1.06B | 1.27B | 881.78M | 906.28M | 614.35M |
| Gross Profit Ratio | 88.22% | 87.19% | 88.29% | 88.31% | 90.38% | 88.95% | 88.96% |
| Research & Development | 208.74M | 133.53M | 156.76M | 93.36M | 65.16M | 61.80M | 41.04M |
| General & Administrative | 59.85M | 59.66M | 28.24M | 16.84M | 20.05M | 105.44M | 20.65M |
| Selling & Marketing | 609.17M | 411.63M | 453.08M | 577.86M | 449.46M | 516.68M | 361.74M |
| SG&A | 850.81M | 471.29M | 481.33M | 594.71M | 469.51M | 622.12M | 382.40M |
| Other Expenses | -14.95M | 87.94M | 78.38M | 106.22M | 66.37M | 385.17K | -1.39M |
| Operating Expenses | 1.06B | 692.76M | 716.46M | 794.29M | 601.04M | 740.62M | 448.32M |
| Cost & Expenses | 1.27B | 829.98M | 857.21M | 962.72M | 694.93M | 853.25M | 524.59M |
| Interest Income | 12.44M | 18.40M | 11.78M | 927.84K | 492.64K | 219.24K | 103.56K |
| Interest Expense | 868.14K | 74.97M | 328.77K | 4.05M | 8.30M | 9.42M | 11.44M |
| Depreciation & Amortization | 99.00M | 76.62M | 69.32M | 59.52M | 42.88M | 31.80M | 15.71M |
| EBITDA | 662.93M | 274.15M | 332.41M | 546.13M | 329.04M | 194.48M | 139.86M |
| EBITDA Ratio | 36.59% | 32.07% | 35.21% | 38.08% | 31.37% | 19.10% | 25.40% |
| Operating Income | 559.29M | 272.67M | 354.93M | 482.17M | 267.88M | 149.43M | 114.09M |
| Operating Income Ratio | 30.87% | 25.45% | 29.53% | 33.45% | 27.46% | 14.67% | 16.52% |
| Total Other Income/Expenses | 4.46M | 10.47M | -335.47K | 222.85K | -4.04M | 3.73M | -1.39M |
| Income Before Tax | 563.76M | 197.69M | 261.57M | 486.65M | 263.84M | 149.81M | 112.71M |
| Income Before Tax Ratio | 31.12% | 18.45% | 21.76% | 33.76% | 27.04% | 14.70% | 16.32% |
| Income Tax Expense | 62.75M | 16.16M | 18.01M | 68.42M | 42.81M | 21.75M | 19.23M |
| Net Income | 501.01M | 181.54M | 243.55M | 418.23M | 221.02M | 128.06M | 93.48M |
| Net Income Ratio | 27.65% | 16.94% | 20.26% | 29.02% | 22.65% | 12.57% | 13.54% |
| EPS | 1.21 | 0.44 | 0.59 | 1.01 | 0.54 | 0.36 | 0.26 |
| EPS Diluted | 1.21 | 0.44 | 0.59 | 1.01 | 0.54 | 0.36 | 0.26 |
| Weighted Avg Shares Out | 414.06M | 412.84M | 412.84M | 412.84M | 412.84M | 355.71M | 359.54M |
| Weighted Avg Shares Out (Dil) | 414.06M | 412.84M | 412.84M | 412.84M | 412.84M | 355.71M | 359.54M |
Source: https://incomestatements.info
Category: Stock Reports